Oleamide: A fatty acid amide signaling molecule in the cardiovascular system?

Cardiovascular Drug Reviews

Volumn 25, Issue 1, 2007, Pages 46-60

  Hiley, C Robin ^a   Hoi, Pui Man ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood pressure; Cannabinoid receptors; Endocannabinoids; Endothelial cells; FAAH; Fatty acid amide hydrolase; Gap junctions; Hypothermia; Oleamide; TRPV1; Vanilloid receptor; Vascular smooth muscle

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 BENZYLOXYPHENYL N BUTYLCARBAMATE; ALPHA AMIDATING ENZYME; ANANDAMIDE; BENZYLSULFONYL FLUORIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DIAZOMETHYLARACHIDONOYL KETONE; DISULFIRAM; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; L 741626; METHYLARACHIDONOYL FLUOROPHOSPHONATE; O 1918; OL 92; OLEAMIDE; OLEOYLTRIFLUOROMETHYL KETONE; PERTUSSIS TOXIN; RIMONABANT; SEROTONIN 7 RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 532; VANILLOID RECEPTOR 1; VOLTAGE GATED SODIUM CHANNEL;

CARDIOVASCULAR EFFECT; CARDIOVASCULAR SYSTEM; DRUG MECHANISM; DRUG SENSITIVITY; ENDOTHELIUM; ENZYME SYNTHESIS; GAP JUNCTION; HUMAN; HYDROLYSIS; HYPERPOLARIZATION; HYPOTHERMIA; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASODILATATION;

AMIDOHYDROLASES; ANIMALS; ARACHIDONIC ACIDS; BODY TEMPERATURE REGULATION; CARDIOVASCULAR SYSTEM; CEREBROSIDES; GAP JUNCTIONS; HUMANS; OLEIC ACIDS; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, GABA-A; RECEPTORS, SEROTONIN; SIGNAL TRANSDUCTION; SODIUM CHANNELS; STEREOISOMERISM; TRPV CATION CHANNELS; VASODILATOR AGENTS;

EID: 34247199450     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00004.x     Document Type: Review

References (83)

1. Abou-Mohamed GA, Huang J, Oldham CD, Taylor AA, Jin L, Caldwell RB, May SW, Caldwell RW. (2000) Vascular and endothelial actions of inhibitors of substance P amidation. J Cardiovasc Pharmacol 35:871-880.
2. 7A receptor by lipidic amphipathic compounds. Mol Pharmacol 60:1349-1355.
3. Arafat ES, Trimble JW, Andersen RN, Dass C, Desiderio DM (1989) Identification of fatty acid amides in human plasma. Life Sci 45:1679-1687.
4. Bannerman P, Nichols W, Puhalla S, Oliver T, Berman M, Pleasure D (2000) Early migratory rat neural crest cells express functional gap junctions: evidence that neural crest cell survival requires gap junction function. J Neurosci Res 61:605-615.
5. Basile AS, Hanus L, Mendelson WB (1999) Characterization of the hypnotic properties of oleamide. Neuroreport 10:947-951.
6. Ben-Shabat S, Fride E, Sheskin T, Tamiri T, Rhee MH, Vogel Z, Bisogno T, De Petrocellis L, Di Marzo V, Mechoulam R (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353:23-31.
7. Bisogno T, Sepe N, De Petrocellis L, Mechoulam R, Di Marzo V (1997) The sleep inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem Biophys Res Commun 239:473-479.
8. Boger DL, Henriksen SJ, Cravatt BF (1998) Oleamide: an endogenous sleep-inducing lipid and prototypical member of a new class of biological signaling molecules. Curr Pharm Des 4:303-314.
9. Boger DL, Patterson JE, Guan X, Cravatt BF, Lerner RA, Gilula NB (1998) Chemical requirements for inhibition of gap junction communication by the biologically active lipid oleamide. Proc Natl Acad Sci USA 95:4810-4815.
10. 1A serotonin receptor potentiation by the biologically active lipid oleamide. Proc Natl Acad Sci USA 95:4102-4107.
11. Boger DL, Sato H, Lerner AE, Hedrick MP, Fecik RA, Miyachi H, Wiekie GD, Austin BJ, Patricelli MP, Cravatt BF (2000) Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anandamide. Proc Natl Acad Sci USA 97:5044-5049.
12. 2+ signaling through gap junctions in airway cells. Am J Physiol Lung Cell Mol Physiol 279:L623-L630.
13. Boring DL, Berglund BA, Howlett AC (1996) Cerebrodiene, arachidonyl-ethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 55:207-210.
14. Bradshaw HB, Walker JM (2005) The expanding field of cannabimimetic and related lipid mediators. Br J Pharmacol 144:459-465.
15. Carai MA, Colombo G, Maccioni P, Gessa GL (2006) Efficacy of rimonabant and other cannabinoid CB1 receptor antagonists in reducing food intake and body weight: Preclinical and clinical data. CNS Drug Rev 12:91-99.
16. Chaperon F, Thiebot MH (1999) Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 13:243-281.
17. Chaturvedi S, Driscoll WJ, Elliot BM, Faraday MM, Grunberg NE, Mueller GP (2006) In vivo evidence that N-oleoylglycine acts independently of its conversion to oleamide. Prostaglandins Other Lipid Mediat 81:136-149.
18. 2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533-541.
19. Childers SR, Sexton T, Roy MB (1994) Effects of anandamide on cannabinoid receptors in rat brain membranes. Biochem Pharmacol 47:711-715.
20. Cooper I, Lord T, Tice PA (1995) Hydrolysis studies on oleamide in simulated gastrointestinal fluids. Food Addit Contam 12:769-777.
21. Coyne L, Lees G, Nicholson RA, Zheng J, Neufield KD (2002) The sleep hormone oleamide modulates inhibitory ionotropic receptors in mammalian CNS in vitro. Br J Pharmacol 135:1977-1987.
22. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384:83-87.
23. Cravatt BF, Prospero-Garcia O, Siuzdak G, Gilula NB, Henriksen SJ, Boger DL, Lerner RA (1995) Chemical characterization of a family of brain lipids that induce sleep. Science 268:1506-1509.
24. Decrouy X, Gasc JM, Pointis G, Segretain D (2004) Functional characterization of Cx43 based gap junctions during spermatogenesis. J Cell Physiol 200:146-154.
25. Deutsch DG, Goligorsky MS, Schmid PC, Krebsbach RJ, Schmid HH, Das SK, Dey SK, Arreaza G, Thorup C, Stefano G, Moore LC (1997) Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 100:1538-1546.
26. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949.
27. Dewey WL (1986) Cannabinoid pharmacology. Pharmacol Rev 38:151-178.
28. Driscoll WJ, Mueller SA, Eipper BA, Mueller GP (1999) Differential regulation of peptide α-amidation by dexamethasone and disulfiram. Mol Pharmacol 55:1067-1076.
29. Ehrlich HP, Sun B, Saggers GC, Kromath F (2006) Gap junction communications influence upon fibroblast synthesis of Type I collagen and fibronectin. J Cell Biochem 98:735-743.
30. Fedorova I, Hashimoto A, Fecik RA, Hedrick MP, Hanus LO, Boger DL, Rice KC, Basile AS (2001) Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J Pharmacol Exp Ther 299:332-342.
31. Fowler CJ (2004) Oleamide: A member of the endocannabinoid family? Br J Pharmacol 141:195-196.
32. Fowler CJ, Borjesson M, Tiger G (2000) Differences in the pharmacological properties of rat and chicken brain fatty acid amidohydrolase. Br J Pharmacol 131:498-504.
33. Giang DK, Cravatt BF (1997) Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 94:2238-2242.
34. Goparaju SK, Kurahashi Y, Suzuki H, Ueda N, Yamamoto S (1999) Anandamide amidohydrolase of porcine brain: cDNA cloning, functional expression and site-directed mutagenesis. Biochim Biophys Acta 1441:77-84.
35. Guan X, Cravatt BF, Ehring GR, Hall JE, Boger DL, Lerner PA, Gilubi NB. (1997) The sleep-inducing lipid oleamide deconvolutes gap junction communication and calcium wave transmission in glial cells. J Cell Biol 139:1785-1792.
36. Hanus LO, Fales HM, Spande TF, Basile AS (1999)Agas chromatographic-mass spectral assay for the quantitative determination of oleamide in biological fluids. Anal Biochem 270:159-166.
37. Hillard CJ, Edgemond WS, Jarrahian A, Campbell WB (1997) Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J Neurochem 69:631-638.
38. Hoi PM, Hiley CR (2006) Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol 147:560-568.
39. Huang GY, Cooper ES, Waldo K, Kirby ML, Gilula NB, Lo CW (1998) Gap junction-mediated cell-cell communication modulates mouse neural crest migration. J Cell Biol 143:1725-1734.
40. 2+ levels in MDCK renal tubular cells. Life Sci 68:997-1004.
41. Huidobro-Toro JP, Harris RA (1996) Brain lipids that induce sleep are novel modulators of 5-hydroxytrypamine receptors. Proc Natl Acad Sci U.S.A. 93:8078-8082.
42. Huitron-Resendiz S, Gombart L, Cravatt BF, Henriksen SJ (2001) Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp Neurol 172:235-243.
43. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Toutini A, Mor M, Tarzia G, Calignano A, Guistino A, et al. (2003) Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9:76-81.
44. Katopodis AG, May SW (1990) Novel substrates and inhibitors of peptidylglycine α-amidating monooxygenase. Biochemistry 29:4541-4548.
45. Kell PJ, Creer MH, Crown KN, Wirsig K, McHowat J (2003) Inhibition of platelet-activating factor (PAF) acetylhydrolase by methyl arachidonyl fluorophosphonate potentiates PAF synthesis in thrombin-stimulated human coronary artery endothelial cells. J Pharmacol Exp Ther 307:1163-1170.
46. Krutovskikh VA, Piccoli C, Yamasaki H (2002) Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 21:1989-1999.
47. Lambert DM, Di Marzo V (1999) The palmitoylethanolamide and oleamide enigmas: are these two fatty acid amides cannabimimetic? Curr Med Chem 6:757-773.
48. Laposky AD, Homanics GE, Basile A, Mendelson WB (2001) Deletion of the GABAA receptor beta 3 subunit eliminates the hypnotic actions of oleamide in mice. Neuroreport 12:4143-4147.
49. Lees G, Edwards MD, Hassoni AA, Ganellin CR, Galanakis D (1998) Modulation of GABAA receptors and inhibitory synaptic currents by the endogenous CNS sleep regulator cis-9,10-octadecenoamide (cOA). Br J Pharmacol 124:873-882.
50. Leggett JD, Aspley S, Beckett SR, D'Antona AM, Kendall DA, Kendall DA (2004) Oleamide is a selective endogenous agonist of rat and human CB1 cannabinoid receptors. Br J Pharmacol 141:253-262.
51. Lerner RA, Siuzdak G, Prospero-Garcia O, Henriksen SJ, Boger DL, Cravatt BF (1994) Cerebrodiene: A brain lipid isolated from sleep-deprived cats. Proc Natl Acad Sci USA 91:9505-9508.
52. 2+-independent phospholipase A2 by methyl arachidonyl fluorophosphonate. Biochim Biophys Acta 1302:55-60.
53. 1 cannabinoid receptor knockout mice of different ages. J Neurochem 78:339-348.
54. Maccarrone M, Bari M, Lorenzon T, Bisogno T, Di Marzo V, Finazzi-Agro A (2000) Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 275:13484-13492.
55. Martinez-Gonzalez D, Bonilla-Jaime H, Morales-Otal A, Henriksen SJ, Velazquez-Moctezuma J, Prospero-Garcia O (2004) Oleamide and anandamide effects on food intake and sexual behavior of rats. Neurosci Lett 364: 1-6.
56. Maurelli S, Bisogno T, De Petrocellis L, Di A, Marino G, Di Marzo V(1995) Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma 'anandamide amidohydrolase'. FEBS Lett 377:82-86.
57. McKinney MK, Cravatt BF (2005) Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74:411-432.
58. Mechoulam R, Fride E, Di Marzo V (1998) Endocannabinoids. Eur J Pharmacol 359:1-18.
59. Mechoulam R, Fride E, Hanus L, et al. (1997) Anandamide may mediate sleep induction. Nature 389:25-26.
60. Merkler DJ, Chew GH, Gee AJ, Merkler KA, Sorondo JP, Johnson ME (2004) Oleic acid derived metabolites in mouse neuroblastoma N18TG2 cells. Biochemistry 43:12667-12674.
61. Nagasawa K, Chiba H, Fujita H, et al. (2006) Possible involvement of gap junctions in the barrier function of tight junctions of brain and lung endothelial cells. J Cell Physiol 208:123-132.
62. Nicholson RA, Zheng J, Ganellin CR, Verdon B, Lees G (2001) Anesthetic-like interaction of the sleepinducing lipid oleamide with voltage-gated sodium channels in mammalian brain. Anesthesiology 94:120-128.
63. O'Byrne J, Hunt MC, Rai DK, Saeki M, Alexson SE(2003) The human bile acid-CoA:amino acid N-acyltransferase functions in the conjugation of fatty acids to glycine. J Biol Chem 278:34237-34244.
64. 9-tetrahydrocannabinol in rat mesenteric vasculature, and its interactions with the endocannabinoid anandamide. Br J Pharmacol 145:514-526.
65. Offertáler L, Mo FM, Batkai S, et al. (2003) Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63:699-705.
66. Pratt PF, Hillard CJ, Edgemond WS, Campbell WB (1998) N-arachidonylethanolamide relaxation of bovine coronary artery is not mediated by CB1 cannabinoid receptor. Am J Physiol 274:H375-H381.
67. Schiller PC, D'Ippolito G, Brambilla R, Roos BA, Howard GA (2001) Inhibition of gap-junctional communication induces the trans-differentiation of osteoblasts to an adipocytic phenotype in vitro. J Biol Chem 276:14133-14138.
68. Schmid HH, Berdyshev EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: Metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66:363-376.
69. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R (1997) Structural requirements for binding of anandamidetype compounds to the brain cannabinoid receptor. J Med Chem 40:659-667.
70. Sugiura T, Kondo S, Kodaka T, Tonegawa T, Nakane S, Yamashita A, Ishima Y, Waku K (1996) Enzymatic synthesis of oleamide (cis-9,10-octadecenoamide), an endogenous sleep-inducing lipid, by rat brain microsomes. Biochem Mol Biol Int 40:931-938.
71. Thomas EA, Carson MJ, Neal MJ, Sutcliffe JG (1997) Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc Natl Acad Sci USA 94:14115-14119.
72. Thomas EA, Carson MJ, Sutcliffe JG (1998) Oleamide-induced modulation of 5-hydroxytryptamine receptor-mediated signaling. Ann N Y Acad Sci 861:183-189.
73. Thomas EA, Cravatt BF, Danielson PE, Gilula NB, Sutcliffe JG (1997) Fatty acid amide hydrolase, the degradative enzyme for anandamide and oleamide, has selective distribution in neurons within the rat central nervous system. J Neurosci Res 50:1047-1052.
74. Vandevoorde S, Lambert DM (2005) Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets. Curr Pharm Des 11:2647-2668.
75. (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task. J Pharmacol Exp Ther 317:251-257.
76. Venance L, Piomelli D, Glowinski J, Giaume C (1995) Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature 376:590-594.
77. + channels in vitro: a putative endogenous ligand for depressant drug sites in CNS. Br J Pharmacol 129:283-290.
78. Walker JM, Krey JF, Chu CJ, Huang SM (2002) Endocannabinoids and related fatty acid derivatives in pain modulation. Chem Phys Lipids 121:159-172.
79. White R, Hiley CR (1997) A comparison of EDHF-mediated and anandamide-induced relaxations in the rat isolated mesenteric artery. Br J Pharmacol 122:1573-1584.
80. White R, Hiley CR (1998) The actions of some cannabinoid receptor ligands in the rat isolated mesenteric artery. Br J Pharmacol 125:533-541.
81. Willoughby KA, Moore SF, Martin BR, Ellis EF (1997) The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther 282:243-247.
82. Yost CS, Hampson AJ, Leonoudakis D, Koblin DD, Bornheim LM, Gray AT (1998) Oleamide potentiates benzodiazepine-sensitive γ-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. Anesth Analg 86:1294-1300.
83. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, DiMarzo Y, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457.